2462-32-0

Basic information

• Product Name: L-Phenylalanine benzyl ester hydrochloride
• Synonyms: benzyl 3-phenyl-L-alaninate hydrochloride;L-Phenylalanine Benzyl Ester HCl;Phenylalanine, benzyl ester hydrochloride;H-PHE-OBZL.HCI;H-L-Phe-OBzl*HCl;Nsc522226;l-phenylalanine benzyl ester hydrovhloride;H-Phe-OBzl hydrochloride
• CAS NO: 2462-32-0
• Molecular Formula: C₁₆H₁₇NO₂*ClH
• Molecular Weight: 291.77
• EINECS: 219-558-3
• Product Categories: Amino Acid Derivatives;Amino Acids;Phenylalanine [Phe, F];Amino Acids and Derivatives;Amino Acid Benzyl Esters;Amino Acids (C-Protected);Biochemistry;Amino hydrochloride;Amino Acid Derivatives;Peptide Synthesis;Phenylalanine
• Mol File: 2462-32-0.mol

Chemical Properties

• Melting Point: 197-200 °C
• Boiling Point: 382.8 °C at 760 mmHg
• Flash Point: 220.4 °C
• Appearance: White to off-white/Crystalline Powder
• Vapor Pressure: 4.62E-06mmHg at 25°C
• Refractive Index: -12 ° (C=1, 80% acetic acid)
• Storage Temp.: Store at RT.
• Water Solubility: Soluble in water
• BRN: 3919200
• CAS DataBase Reference: L-Phenylalanine benzyl ester hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: L-Phenylalanine benzyl ester hydrochloride(2462-32-0)
• EPA Substance Registry System: L-Phenylalanine benzyl ester hydrochloride(2462-32-0)

Safety Data

• Safety Statements: 22-24/25
• WGK Germany: 3
• Hazardous Substances Data: 2462-32-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
L-Phenylalanine benzyl ester hydrochloride is used as a key reactant for the synthesis of L-isoserine derivatives, which are known as aminopeptidase N inhibitors. These inhibitors play a significant role in the development of drugs targeting various diseases, including cancer and neurodegenerative disorders.
L-Phenylalanine benzyl ester hydrochloride is also used as a reactant in the synthesis of PF-04449913, a potent and orally bioavailable inhibitor of the smoothened protein. L-Phenylalanine benzyl ester hydrochloride has potential applications in the treatment of various cancers, as it can help regulate the Hedgehog signaling pathway, which is often dysregulated in cancer cells.

InChI:InChI=1/C16H17NO2.ClH/c17-15(11-13-7-3-1-4-8-13)16(18)19-12-14-9-5-2-6-10-14;/h1-10,15H,11-12,17H2;1H/t15-;/m0./s1

Upstream product

• 100-51-6 benzyl alcohol 
• 100-39-0 benzyl bromide 
• 13734-34-4 N-tert-butoxycarbonyl-L-phenylalanine 
• 63-91-2 L-phenylalanine 
• 58780-66-8 phenylalanine benzyl ester hydrochloride 
• 100-44-7 benzyl chloride 
• 66617-58-1 N-(tert-butoxycarbonyl)-L-phenylalanine benzyl ester 
• 2688-22-4 Nps-L-Phe-OH 
• 84673-44-9 (S)-2-(2-Nitro-phenylsulfanylamino)-3-phenyl-propionic acid benzyl ester 

Downstream Products

• 406478-97-5 (2R)-2-(prop-2-enyl)-5-oxoprolyl-L-phenylalanine benzyl ester 
• 406479-06-9 (2R)-1-(4-methoxybenzyl)-2-(prop-2-enyl)-5-oxoprolyl-L-phenylalanine benzyl ester 
• 406478-98-6 N^α-[(5R,8RS)-8-hydroxy-2,6-dioxo-1-azaspiro[4.4]octyl]-L-phenylalanine benzyl ester 
• 406479-02-5 (S)-1-[(S)-2-((R)-2,6-Dioxo-1,7-diaza-spiro[4.4]non-8-en-7-yl)-3-phenyl-propionyl]-pyrrolidine-2-carboxylic acid amide 
• 406478-99-7 N^α-[(5R,8RS)-8-tert-butyldimethylsilyloxy-2,6-dioxo-1-azaspiro[4.4]octyl]-L-phenylalanine benzyl ester 
• 406479-01-4 N^α-[(5R,8RS)-8-tert-butyldimethylsilyloxy-2,6-dioxo-1-azaspiro[4.4]octyl]-L-phenylalanyl-L-prolinamide 
• 70691-56-4 L-leucyl-L-phenylalanine methyl ester hydrochloride 
• 1365292-17-6 L-isoseryl-L-phenylalanine benzyl ester hydrochloride 
• 1365292-39-2 L-isoseryl-L-leucyl-L-phenylalanine benzyl ester hydrochloride 
• 1365292-26-7 C₁₂H₁₆N₂O₄*ClH 
• 1365292-52-9 L-isoseryl-L-leucyl-L-phenylalanine hydrochloride 
• 1391931-80-8 (S)-benzyl 2-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-3-phenylpropanoate 
• 1391931-83-1 C₁₈H₁₇NO₅ 
• 1391931-84-2 (S)-N-(1-(1-methylhydrazinyl)-1-oxo-3-phenylpropan-2-yl)-2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamide 

Relevant articles and documents

Fluorinated epoxyketone-based compounds and uses thereof as proteasome inhibitors

The present application relates to novel fluorinated epoxyketone-based compounds, compositions comprising these compounds and their use, in particular for the treatment of diseases, disorders or conditions mediated by proteasome inhibition, in particular, the present application includes compounds of Formula I, and compositions and uses thereof.

Chiral recognition of carboxylates by a static library of thiourea receptors with amino acid arms

Chiral recognition is based on a large network of very subtle interactions whose outcome is difficult to predict. A combinatorial approach is therefore the most suitable to search for the most efficient receptor and obtain a structure-enantioselectivity correlation. We synthesized a set of 12 receptors constructed with 1,9-diaminoantracene and α-amino acid esters, linked via thiourea groups. The association constants and enantioselectivities for the complexes with mandelate and N-acetylphenylalanine were determined by competitive NMR titrations. Association constants quite regularly depend on the substituents in the receptor structure, but the distribution of enantioselectivities across the library could not easily be rationalized.

Design, synthesis and biological evaluation of potent azadipeptide nitrile inhibitors and activity-based probes as promising anti-Trypanosoma brucei agents

Trypanosoma cruzi and Trypanosoma brucei are parasites that cause Chagas disease and African sleeping sickness, respectively. There is an urgent need for the development of new drugs against both diseases due to the lack of adequate cures and emerging drug resistance. One promising strategy for the discovery of small-molecule therapeutics against parasitic diseases has been to target the major cysteine proteases such as cruzain for T. cruzi, and rhodesain/TbCatB for T. brucei. Azadipeptide nitriles belong to a novel class of extremely potent cysteine protease inhibitors against papain-like proteases. We herein report the design, synthesis, and evaluation of a series of azanitrile-containing compounds, most of which were shown to potently inhibit both recombinant cruzain and rhodesain at low nanomolar/picomolar ranges. A strong correlation between the potency of rhodesain inhibition (i.e., target-based screening) and trypanocidal activity (i.e., whole-organism-based screening) of the compounds was observed. To facilitate detailed studies of this important class of inhibitors, selected hit compounds from our screenings were chemically converted into activity-based probes (ABPs), which were subsequently used for in situ proteome profiling and cellular localization studies to further elucidate potential cellular targets (on and off) in both the disease-relevant bloodstream form (BSF) and the insect-residing procyclic form (PCF) of Trypanosoma brucei. Overall, the inhibitors presented herein show great promise as a new class of anti-trypanosome agents, which possess better activities than existing drugs. The activity-based probes generated from this study could also serve as valuable tools for parasite-based proteome profiling studies, as well as bioimaging agents for studies of cellular uptake and distribution of these drug candidates. Our studies therefore provide a good starting point for further development of these azanitrile-containing compounds as potential anti-parasitic agents. Copyright

Synthesis of a novel series of L-isoserine derivatives as aminopeptidase N inhibitors

A series of novel L-isoserine derivatives were synthesised and evaluated for their ability to inhibit aminopeptidase N (APN)/CD13. In our preliminary biological results, some of these compounds possessed a potent inhibitory activity against the APN. Within this series, compound 14b not only showed similar enzyme inhibition (IC50 of 12.2μM) compared with the positive control bestatin (half maximal inhibitory concentration (IC 50) of 7.3μM), but also had a potent antiproliferative activity against human cancer cell lines cells.

COMPOSITIONS AND METHODS FOR CYCLOFRUCTANS AS SEPARATION AGENTS

The present invention relates to derivatized cyclofructan compounds, compositions comprising derivatized cyclofructan compounds, and methods of using compositions comprising derivatized cyclofructan compounds for chromatographic separations of chemical species, including enantiomers. Said compositions may comprise a solid support and/or polymers comprising derivatized cyclofructan compounds.

Esterification of unprotected a-Amino acids in ionic liquids as the reaction media

Ionic liquid 1,3-dimethylimidazolium methanesulfonate was used to prepare a-amino acids benzylic esters from unprotected amino acids and benzyl chloride. Esterification of several amino acids was achieved with satisfactory yields: by-products can be removed by a simple work-up procedure to afford the pure product. The described method is simple, mild, rapid and save.

A class of novel carboline intercalators: Their synthesis, in vitro anti-proliferation, in vivo anti-tumor action, and 3D QSAR analysis

Based on DOCK scores 18 N-(3-benzyloxycarbonylcarboline-1-yl)ethylamino acid benzylesters (6a-r) were synthesized as anti-tumor agents. Their IC 50 values against five human carcinoma cell lines ranged from 11.1 μM to more than 100 μM. The in vivo assay identified five derivatives of them had no anti-tumor action, the anti-tumor activity of nine derivatives of them equaled that of cytarabine, and the anti-tumor activity of three derivatives of them was higher than that of cytarabine. The UV and fluorescence spectra, as well as the relative viscosity and melting temperature measurements of calf thymus DNA (CT DNA) with and without the representative compound suggested that DNA intercalation could be their action mechanism. The 3D QSAR analysis of N-(3-benzyloxycarbonylcarboline-1-yl)ethylamino acid benzylesters (6a-r) revealed that their in vivo anti-tumor activity significantly depends on the molecular electrostatic and steric fields of the side chain of the amino acid residue.

Study on synthesis, characteristics and catalysis properties of novel chiral metal complexes catalysts for 1,3-dipolar cycloaddition reactions of nitrone with electron-rich alkene

As a new class of potential catalysts for 1,3-dipolar cycloaddition reactions, fourteen L-amino acid Schiff base Cu(II) and Ti(IV) complexes were synthesized, characterized, and evaluated for their catalytic activities in the reaction between C, N-diphenylnitrone and electron-rich ethyl vinyl ether under both homogeneous and in situ conditions. The methods for preparation and utilization of the catalysts were elucidated in detail, and the results of the catalytic reactions were described and discussed as well. Excellent reaction results were found in the presence of some catalysts (20 mol%) with > 90% endo-isoazolidines produced, compared with predominantly exo-isoazolidine produced without a catalyst. In addition, the reaction rate is found to be enhanced remarkably by a Cu(II) complex Schiff base catalyst at room temperature.

Sulfonic acid derivatives of hydroxamic acids and their use as medicinal products

The present invention relates to a novel sulfonic acid derivative of hydroxamic acid or a pharmacologically acceptable salt thereof. More particularly, the present invention relates to a sulfonic acid derivative of hydroxamic acid or a pharmacologically acceptable salt thereof, which is useful as an inhibitor of lipopolysaccharides (LPS). In addition, the present invention relates to a novel intermediate compound useful for the synthesis of this sulfonic acid derivative of hydroxamic acid.

Cell adhesion antagonists: Synthesis and evaluation of a novel series of phenylalanine based inhibitors

Several phenylalanine based inhibitors were synthesized as antagonists of the leukocyte cell adhesion process that is mediated through the interactions of the mucosal addressin cell adhesion molecule (MAdCAM) and the intgerin α4β7. Analogues 20, 21, 22 and 24 displayed inhibition of adhesion in a cell based assay in the low micromolar range. (C) 2000 Published by Elsevier Science Ltd.